Swiss National Bank Humanigen, Inc Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.76 - $3.33 $212,432 - $401,931	-120,700 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$1.81 - $3.97 $29,141 - $63,917	16,100 Added 15.39%	120,700 $363,000
Q4 2021 Feb 08, 2022	BUY	$3.66 - $8.22 $123,342 - $277,014	33,700 Added 47.53%	104,600 $389,000
Q2 2021 Aug 06, 2021	BUY	$13.54 - $22.74 $959,985 - $1.61 Million	70,900 New	70,900 $1.23 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.